| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
Emory University School of Medicine, Atlanta, Georgia 30322 [M. R. G.]; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114 [J. G. S., T. B.]; Wake Forest University School of Medicine, Winston-Salem, North Carolina [G. L.]; and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland [J. D. F., S. P., S. G.]
Purpose: A preliminary evaluation of the efficacy of irinotecan in patients with malignant glioma demonstrated modest activity. A markedly lower than expected incidence of drug-related toxicity was also noted. This was consistent with pharmacokinetic data indicating that the total body clearance (CL) of irinotecan in this patient population was considerably greater than in colorectal cancer patients. Concomitant medications used chronically in brain cancer patients, especially glucocorticoids and anticonvulsants that induce hepatic enzymes involved in the metabolism or excretion of drugs, were believed to be the cause of the alteration in pharmacokinetic behavior. A Phase I study was therefore undertaken in patients with recurrent malignant gliomas to independently determine the maximum tolerated dose (MTD) of irinotecan in patients stratified according to the use of enzyme-inducing anticonvulsants (EIAs).
Experimental Design: Patients with recurrent malignant gliomas received irinotecan as a weekly 90-min i.v. infusion for four consecutive weeks, with additional cycles of treatment repeated every 6 weeks. The starting dose was 125 mg/m2/week for both groups of patients (+/-EIA). Groups of 
3 patients were evaluated at each dose level, and the modified continual reassessment method was used for dose adjustments. The plasma pharmacokinetics of irinotecan, its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), and the glucuronide conjugate of SN-38, SN-38 glucuronide, were determined in all patients during treatment with the first weekly dose.
Results: Forty patients were enrolled into the study and treated with a total of 135 cycles of irinotecan. The MTD was determined to be 411 mg/m2/week in the +EIA cohort and 117 mg/m2/week in the -EIA cohort for the weekly x 4 every 6 weeks schedule. Pharmacokinetic studies showed that the CL of irinotecan was distinctly dose dependent in the patients receiving EIAs, decreasing from 
50 liters/h/m2 at the lower dose levels (125–238 mg/m2) to a mean ± SD value of 29.7 ± 9.0 liters/h/m2 (n = 7) at the MTD. The grand mean CL for a group of 13 patients who were not taking EIAs, 18.8 ± 10.6 liters/h/m2, was significantly different from the mean CL at the MTD of the +EIA cohort (P = 0.033). Mean values of the AUC of SN-38 (P = 0.4) and SN-38 glucuronide (P = 0.55) were not significantly different at the MTDs for the two cohorts of patients.
Conclusions: The MTD of irinotecan was 3.5 times greater in patients with malignant glioma who were concurrently receiving EIAs than in those who were not. This study has also served to confirm that the concomitant administration of EIAs results in marked enhancement in the CL of irinotecan. These findings have important implications for subsequent clinical trials to further evaluate irinotecan in brain cancer patients and underscore the importance of assessing the potential for pharmacokinetic interactions between concurrent medications and chemotherapeutic agents.
This article has been cited by other articles:
|
|
 |
|
  S. A. Grossman, J. Olson, T. Batchelor, D. Peereboom, G. Lesser, S. Desideri, X. Ye, T. Hammour, J. G. Supko, and for the New Approaches to Brain Tumor Therapy CNS Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma Neuro-oncol, April 1, 2008; 10(2): 190 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. K. Puduvalli, P. Giglio, M. D. Groves, K. R. Hess, M. R. Gilbert, S. Mahankali, E. F. Jackson, V. A. Levin, C. A. Conrad, S. H. Hsu, et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme Neuro-oncol, April 1, 2008; 10(2): 216 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Loghin, M. D. Prados, P. Wen, L. Junck, F. Lieberman, H. Fine, K. L. Fink, M. Metha, J. Kuhn, K. Lamborn, et al. Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study Clin. Cancer Res., December 1, 2007; 13(23): 7133 - 7138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Carson, S. A. Grossman, J. D. Fisher, and E. G. Shaw Prognostic Factors for Survival in Adult Patients With Recurrent Glioma Enrolled Onto the New Approaches to Brain Tumor Therapy CNS Consortium Phase I and II Clinical Trials J. Clin. Oncol., June 20, 2007; 25(18): 2601 - 2606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Grossman, K. A. Carson, T. T. Batchelor, G. Lesser, T. Mikkelsen, J. B. Alavi, S. Phuphanich, T. Hammour, J. D. Fisher, and J. G. Supko The Effect of Enzyme-Inducing Antiseizure Drugs on the Pharmacokinetics and Tolerability of Procarbazine Hydrochloride Clin. Cancer Res., September 1, 2006; 12(17): 5174 - 5181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. O. Noble, M. T. Krauze, D. C. Drummond, Y. Yamashita, R. Saito, M. S. Berger, D. B. Kirpotin, K. S. Bankiewicz, and J. W. Park Novel Nanoliposomal CPT-11 Infused by Convection-Enhanced Delivery in Intracranial Tumors: Pharmacology and Efficacy. Cancer Res., March 1, 2006; 66(5): 2801 - 2806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Furman, K. R. Crews, C. Billups, J. Wu, A. J. Gajjar, N. C. Daw, C. C. Patrick, C. Rodriguez-Galindo, C. F. Stewart, J. S. Dome, et al. Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors J. Clin. Oncol., February 1, 2006; 24(4): 563 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Phuphanich, S. D. Baker, S. A. Grossman, K. A. Carson, M. R. Gilbert, J. D. Fisher, and M. A. Carducci Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study Neuro-oncol, April 1, 2005; 7(2): 177 - 182. [Abstract] [PDF]
|
|
|
|
|
|
S. A. Grossman, J. B. Alavi, J. G. Supko, K. A. Carson, R. Priet, F. A. Dorr, J. S. Grundy, and J. T. Holmlund Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-{alpha} delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas Neuro-oncol, January 1, 2005; 7(1): 32 - 40. [Abstract] [PDF]
|
|
|
|
|
|
F. M. Boyle, S. L. Eller, and S. A. Grossman Penetration of intra-arterially administered vincristine in experimental brain tumor Neuro-oncol, October 1, 2004; 6(4): 300 - 306. [Abstract] [PDF]
|
|
|
|
|
|
T. T. Batchelor, M. R. Gilbert, J. G. Supko, K. A. Carson, L. B. Nabors, S. A. Grossman, G. J. Lesser, T. Mikkelsen, S. Phuphanich, and for the NABTT CNS Consortium Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11 Neuro-oncol, January 1, 2004; 6(1): 21 - 27. [Abstract] [PDF]
|
|
|
|
|
|
M. D. Prados, W.K.A. Yung, K. A. Jaeckle, H. I. Robins, M. P. Mehta, H. A. Fine, P. Y. Wen, T. F. Cloughesy, S. M. Chang, M. K. Nicholas, et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study Neuro-oncol, January 1, 2004; 6(1): 44 - 54. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
